2 papers
stat.ME2025
Estimands for Early Phase Dose Optimization Trials in Oncology
Ayon Mukherjee, Jonathan L. Moscovici, Zheng Liu
Phase I dose escalation trials in oncology generally aim to find the maximum tolerated dose (MTD). However, with the advent of molecular targeted therapies and antibody drug conjug…
stat.ME2025
Estimands for Randomized Discontinuation Designs in Oncology
Ayon Mukherjee, Oleksandr Sverdlov, Ngoc-Thuy Ha +1
Randomized discontinuation design (RDD) is an enrichment strategy commonly used to address limitations of traditional placebo-controlled trials, particularly the ethical concern of…